Dyne治疗药物DYNE -101 获得FDA的快车道 治疗1型脑萎缩 Dyne Therapeutics' drug DYNE-101 gets FDA Fast Track for treating myotonic dystrophy type 1.

Dyne Therapeutics 的药物 DYNE-101 已获得 FDA 的快速通道资格，该药物旨在治疗 1 型强直性肌营养不良症，这是一种罕见的神经肌肉疾病。 Dyne Therapeutics has received Fast Track designation from the FDA for its drug DYNE-101, designed to treat myotonic dystrophy type 1, a rare neuromuscular disease. 这一快速审查程序将有助于Dyne在2026年上半年寻求该药物的加速核准。 This expedited review process will help Dyne seek accelerated approval for the drug in the first half of 2026. 目前,DYNE-101正处于临床试验第1/2阶段,显示出给病人带来重大功能效益的可喜结果。 Currently, DYNE-101 is in Phase 1/2 clinical trials, showing promising results with significant functional benefits for patients.